Takeda to Acquire Paradigm Therapeutics

    OSAKA, JAPAN & CAMBRIDGE, ENGLAND, March 12 /CNW/ - Takeda Pharmaceutical
Company Limited ("Takeda")(TOKYO:4502) today announced that Takeda and
Paradigm Therapeutics Limited ("Paradigm") agreed on March 12, 2007 to the
acquisition of Paradigm by Takeda. Paradigm shareholders were advised by Avlar
BioVentures Limited. Financial terms were not disclosed. Subject to
completion, which is expected to occur within a few weeks, Paradigm will
become a subsidiary of Takeda Europe Holdings B.V., a wholly owned subsidiary
of Takeda. Additionally, Paradigm will be renamed Takeda Cambridge Limited,
and Paradigm's subsidiary in Singapore will be renamed Takeda Singapore Pte

    Founded in 1999 by University of Cambridge researchers, Paradigm has
established world-class target identification and validation capabilities
based on genetic engineering and in vivo pharmacology. Using their
capabilities, Paradigm has already developed a promising pipeline of novel
drug discovery targets and compounds in key areas of unmet medical need
including pain, CNS disorders, prostate and breast cancer, diabetes,
hyperlipidemia, and obesity.

    With this merger, which replaces and builds upon Takeda and Paradigm's
2005 CNS therapeutic area alliance, Paradigm's technologies and researchers
will be integrated into Takeda and will help to accelerate multiple scientific
processes such as the validation of drug targets derived from genomic
research, the creation of animal models reflecting the human pathologic
conditions, and the optimization of drug candidates.

    "Takeda have been an excellent partner in our CNS collaboration and this
deal represents a logical and positive extension to that. The company looks
forward to continuing with its drug discovery and development activities
within the global reach and long term planning horizons of Takeda," said
Alastair Riddell, CEO of Paradigm.

    "We are very excited with this deal, which will add to Takeda another
research base equipped with the state-of-the-art technologies expected to
further improve Takeda's research efficiency," said Yasuchika Hasegawa,
President of Takeda. "We now have research functions in Japan, the U.S.,
Europe, and in Singapore where Paradigm has its subsidiary. This acquisition
surely represents our initiatives for establishing global research
infrastructures and for pursuing the world's highest standard of productivity,
which we believe will support enhancement of our R&D pipeline as source for
future growth, and the realization of our goal to become a truly world-class
pharmaceutical company."

    About Paradigm

    Paradigm is a private venture capital backed drug discovery and
development company located on the Cambridge Science Park in Cambridge UK and
Biopolis in Singapore. Paradigm acquired Amedis Pharmaceuticals in December
2004, and Paradigm signed collaboration agreement in June 2005 with Takeda
Pharmaceutical Company.

    About Takeda

    Located in Osaka, Japan, Takeda is a research-based global company with
its main focus on pharmaceuticals. As the largest pharmaceutical company in
Japan and one of the global leaders of the industry, Takeda is committed to
striving toward better health for individuals and progress in medicine by
developing superior pharmaceutical products.

For further information:

For further information: Takeda Pharmaceutical Company Limited Corporate
Communications Dept. Seizo Masuda, +81 (0) 6 6204 2060 or Paradigm
Therapeutics Limited Chief Scientific Officer Dr. Mark Carlton, +44 12 23 477
910 or Paradigm Therapeutics Singapore Pte Limited Director of Research Dr.
Ian Gray, +65 677 11 300

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890